Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourExpanding
15 minDescending Triangle
5 minExpanding
Daily trend turns up above $0.37
Key levels
Resistance$0.29
Resistance$0.24
Support$0.16
Latest news & SEC filings
SEC FilingSenti Biosciences Holdings, Inc. filed a report on a major company event (Form 8-K)
All SNTI news →Senti Biosciences creates treatments that use engineered cells and genes, built around its synthetic gene circuit technology. Its main program, SENTI-202, uses immune cells taken from healthy adult donors to fight blood cancers including acute myeloid leukemia, and is in an early human study across the United States and Australia. The company also has earlier-stage work in solid tumors and a partnership with BlueRock Therapeutics focused on regenerative medicine.
Based on the company's 10-K filed Mar 27, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SNTI.
Start Free Trial →Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
0
Moat Score
NONE
2/9
Piotroski Score
-13.9
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Rajangam Kanya | officer | Sale | 19,953 | - | Oct 21, 2026 |
| Lu Timothy K | director officer | Sale | 157,312 | - | Oct 21, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-99.1%
3yr Revenue CAGR
N/A%
EPS Growth YoY
77.31%
FCF Growth YoY
-5.3%
Revenue Trend
DECLINING
SEPT Investing tracks real-time dark pool institutional trades for SNTI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:03:56 | $0.16 | 1,500 | $$235 | SELL |
| 13:07:13 | $0.16 | 1,001 | $$165 | SELL |
| 13:05:04 | $0.16 | 2,314 | $$378 | SELL |
| 13:04:59 | $0.16 | 6,636 | $$1K | SELL |
| 10:36:10 | $0.17 | 1,035 | $$176 | BUY |
5 dark pool trades shown · $$2K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Senti Biosciences Holdings, Inc. (SNTI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Senti Biosciences Holdings, Inc. (SNTI) is at $0.16, up 11.81% (+$0.02) at the Nov 11, 2026 close.
Latest SNTI news — Nov 10, 2026: Senti Biosciences Holdings, Inc. filed a report on a major company event (Form 8-K)
Analyst ratings for SNTI: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
SNTI last reported on Aug 13, 2026: EPS -$0.41 vs -$0.27 expected — a miss of 54.7%.
SNTI does not currently pay a dividend.
Support: $0.16. Resistance: $0.24, $0.29, $0.33.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 10, 2026: Senti Biosciences Holdings, Inc. filed a report on a major company event (Form 8-K)